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Abstract 
 Low back pain affects nearly 85% of the population of the United States, and is 
associated with a huge socioeconomic burden. One of the leading causes of low back pain is 
Intervertebral Disc (IVD) degeneration, which results in an ingrowth of blood vessels and 
neurites, as well as a sensitization of those neurites. Previous research has indicated that both 
Aggrecan plays a role in regulating angiogenesis in the IVD, and Aggrecan has also been shown 
to inhibit neurogenesis and sensitize neurites. However, it is unclear which components of 
Aggrecan control its inhibitory effects. The goal of this study was to determine how intact and 
degraded Chondroitin Sulfate groups, the dominant side-chains of Aggrecan, affect angiogenesis 
in vitro, as well as the sensitization of neurites. Human Umbilical Vein Endothelial Cells 
(HUVECs) were cultured with either intact or degraded Chondroitin Sulfate-A (CSA), 
Chondroitin Sulfate-B (CSB), or Chondroitin Sulfate-C (CSC) at a concentration of either 10 
µg/ml or 100µg/ml for 16 hours during a tubular formation assay. The tubular assay was 
quantified for total tubular length using the Angiogenesis Analyzer plugin for Image J. The assay 
showed that no inhibition occurred for any of the groups, and that pro-angiogenic effects were 
observed for the 100µg/ml concentration of degraded CSC. The protocol developed to 
investigate the effect of Aggrecan on neurite sensitization involved optimizing the methodology 
for extracting Dorsal Root Ganglia (DRGs) cells from mice for use as a primary cell model. The 
protocol developed is based on literature, but optimizes for simplicity, time, and reduction in the 
cost of surgical instruments. This protocol achieves these goals, and attains high viability for 
DRG cell clusters, but fails to consistently retrieve viable cells from the intact DRGs This study 
sought to investigate the role chondroitin sulfate side chains play in angiogenesis, and it found 
evidence that the degraded factors can have pro-angiogenic effects. The study also sought to 
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develop a protocol that could be used to aggrecan in the role of sensitization, and it improved the 
speed and simplicity of existing procedures.  
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Introduction 
Lower back pain affects nearly 85% of people in the United States at some point in their 
lives1, and results in a significant social and economic burden2. Degeneration of the 
intervertebral disc (IVD) has been implicated in its development, but its mechanisms are still not 
fully understood3. Intervertebral disc disease severely weakens the structure of the disc, and 
often leads to disc herniation4. Disc herniation, or a pressing of disc tissue onto adjacent sensory 
nerves, is one of the main causes of the pain associated with the disease5. However, many 
patients experience intense pain associated with the disease in the absence of herniation. In these 
cases, angiogenesis, or ingrowth of blood vessels, as well as ingrowth of nerves, neurogenesis, 
are commonly reported3. It is this component of intervertebral disc disease that this paper will 
examine. 
Anatomical Review 
A healthy IVD contains several important components that contribute to its functionality as seen 
in Figure 1, below. 
 
Figure 1: Anatomy of the Intervertebral Disc between two vertebral bodies6 
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The core of the IVD is the Nucleus pulposus (NP), which consists of elastin and collagen 
II fibers contained in a hydrated Aggrecan-containing gel. The proteoglycans present in this 
region make up approximately 15% of its wet weight while the remaining majority space 
contains water.7 This water is drawn into the disc via Aggrecan, which maintains a high osmotic 
pressure in order to keep the cushion-like nature of the disc8. The NP contains few cells, with a 
low density of chondrocyte-like cells9. In a healthy disc, no blood vessels or nerves are present, 
and nutrition stems entirely from diffusion. 
Outside the NP is the Anulus Fibrosus (AF) region, which has a similar makeup to the 
NP, but has a much higher collagen concentration. Collagen fibers provide the structure 
necessary for its lamellar structure, and provide substantial strength7. Cells in this region tend to 
be more fibroblast-like, yet blood vessels and nerves are still not typical of the native 
environment, and again nutrition comes from diffusion. 
The Cartilaginous endplate separates the disc from the adjacent vertebral bodies, and is 
generally highly porous and somewhat vascularized to allow for nutritional supply to the rest of 
the disc10. Nociceptive nerves terminate in this region and do not penetrate the disc itself in 
healthy disc tissue.7 
Unhealthy Intervertebral Disc Microenvironment 
 When Intervertebral Disc Degeneration (IVDD) manifests, the biochemical and cellular 
makeup of the disc substantially changes. The matrix degrades as a result of an upregulation of 
inflammatory cytokines. One of the main targets of this degradation is Aggrecan, and as a result 
the disc loses significant hydrostatic pressure11. In addition, resulting from the degradation, the 
normally aneural and avascular IVD is penetrated by both nociceptive nerve fibers3 and blood 
vessels12. Sensitization of neurites has also been observed as a result, and is of significant note. 
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Aggrecan as a Potential Mechanism for Neurovascular Ingrowth 
 As mentioned, Aggrecan, an important structural proteoglycan in the disc, degrades in 
IVDD. While this proteoglycan primarily controls the hydration of the disc, it also has been 
shown to have an important role in regulation of neurovascular ingrowth.  Presence of Aggrecan 
has been shown to inhibit nerve ingrowth into the intervertebral disk13,14, and its degradation in 
degenerative IVDs indicates it is highly important to degenerative disc disease14. Aggrecan has 
also been shown to inhibit angiogenesis, the penetration of blood vessels into the normally 
avascular disc15. Aggrecan contains both a core protein, and a series of side-chains, see Figure 2 
below.  
 
Figure 2: Structure of Intact Aggrecan
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Human Aggrecan has a variety of molecular side-chains that, while intact, could 
contribute to the inhibition of angiogenesis including: 0S iduronic acid, 4S galactosamine, and 
6S galactosamine17. Both these side-chains and the Aggrecan core protein degrade in a 
degenerate disc.  Previous research has indicated that intact Aggrecan with attached side chains 
has an inhibitory effect18, but whether this is due to the core or those side chains is unclear. The 
specific mechanism of inhibition for neurovascular ingrowth is an important detail to determine. 
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Previous research has also demonstrated that relative concentration of Chondroitin – 6 -Sulfate 
increases with age in bovine tissue for both the AF and the NP compared to Chondroitin – 4 -
Sulfate, and Chondroitin – 0 -Sulfate, which together make up the majority of the Chondroitin 
Sulfate side-chain composition19. Because there is a difference between the relative abundance of 
the different Chondroitin Sulfate groups for different ages in Bovine tissue, it could provide 
some insight into how the relative groups affect angiogenesis. In addition, degraded side-chains 
and core monomer could provide the necessary materials necessary for neurovascular growth, 
and could actually be aiding in the ingrowth of blood vessels and nerves.  
Relevance 
 Investigating the mechanisms for the processes of neurovascular ingrowth and 
sensitization in IVDD, which are not fully understood, could result in better long-term treatment 
for the disease. If this project can determine which specific chondroitin sulfate side-chain of 
Aggrecan is having the inhibitory effect on neurovascular ingrowth, targeted treatment can be 
developed that can prevent or reverse these processes. In addition, determining the specific 
factors that affect the sensitization of neurites in IVD disease could result in the development of 
treatments that reduce the pain associated with this effect. 
Specific Aims and Hypotheses 
Aim 1: To determine how degraded Aggrecan products will affect the growth of blood vessels. 
We hypothesize that intact Aggrecan side-chains will inhibit angiogenesis, while degraded side-
chains will aid in angiogenesis. 
Aim 2: To develop a protocol that will allow our lab to isolate mouse dorsal root ganglia (DRGs) 
for use in determining how Aggrecan affects neurite sensitivity. 
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Methodology 
Angiogensis Experiments 
Cell Culture 
 Human Umbilical Vein Endothelial Cells (HUVECs, Cascade Biologics, C-015-5C) were 
cultured in Phenol red-free media(Gibco M200PRF500) supplemented with 1% Penn-Strep (Gibco 
15140-122) and 2% Low Serum Growth Supplement (Cascade Biologics, S-003-10). They were grown 
inside of plastic culture flasks (VWR Tissue Culture Flasks 10062-864) at 37°C with 5% CO2 in an 
incubator (OASIS). The cells were passaged when they reached 70-90% confluency. 
Aggrecan Source 
 To study the effect of Aggrecan on angiogenesis, we used a series of commercially available 
Aggrecan sources which modeled the side-chains present in human Aggrecan. Chondroitin Sulfate-A 
(CS-C0) contains a high amount of Chondroitin-6-Sulfate, which can be used to model 6S Galactosamine. 
Chondroitin Sulfate-B (CS-B) contains a high amount of dermatan-4-sulfate, which can be used to model 
4S Galactosamine. Chondroitin Sulfate-C (CS-A) contains high amounts of Chondroitin-4-Sulfate, which 
contains a high amount of 0S glucuronic acid. Each Chondroitin Sulfate side chain derives from shark due 
to its similarity to its human analog, and its ease of access. 10.0 mg/mL stock concentrations were made 
for each Aggrecan side chain (CSA, CSB, CSC) by dissolving side chain solid in sterile H2O at a ratio of 
10 mg per mL. All stock solutions were aliquoted into 1 ml aliquots and stored in a -20°C freezer. 
Aggrecan Degradation 
 To create the degraded Aggrecan necessary for experiments, 50ul of Chondroitinase-ABC  was 
used per 10 ml media at the desired concentration. This media was then sterile filtered using a 0.2 µm 
pore-sized filter due to the non-sterility of the commercial Chondroitinase-ABC. To create the desired 
concentration of Chondroitinase-ABC, 5 units of Chondroitinase-ABC (Chondroitinase ABC from 
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Proteus Vulgaris, C3667-5UN) was suspended in a solution of 0.5mL of 1M TRIS, .0490g sodium 
acetate, .002g BSA, and 9.5 ml of H2O.  
 To test the efficacy of the degradation of Chondroitin using Chondroitinase-ABC, a Dimethyl-
Methylene Blue (DMMB) assay was used to quantify the amount of intact chondroitin sulfate present for 
both intact and degraded samples of chondroitin sulfate of the same concentration.  
Experimental Media Conditions 
 All conditioned media contained Medium 200 phenol red free + 100U/ml penicillin-100 
µg/ml streptomyocin + low serum growth supplement. Media was generated with 10µg/ml or 
100µg/ml of intact or degraded Chondroitin Sulfate, for each side chain, CSA, CSB, or CSC. 
Degraded media was created by first creating twice the necessary volume of the corresponding 
concentration of intact media. This media was then split, and Chondroitinase-ABC was added to 
half, as described in the previous section.  
HUVEC Angiogenesis Assay 
 HUVEC functional angiogenesis assays are a way to quantify an otherwise in vivo 
process on a surface in vitro. To perform this assay, HUVECs were expanded to 80% confluency 
at a passage of less than 10. While the cell line is immortalized, HUVECs sometimes exhibit a 
change in morphology given enough proliferation in vitro. After thawing Geltrex basement 
membrane (Gibco, A14132-02) overnight, 100µl was added to each well of a 24 – well plate, 
keeping the Geltrex on ice. The plates were then put in a 37°C incubator for 30 minutes to gel. 
HUVECs were then trypsonized and resuspended in their respective media conditions. 6 
different conditions were used, including the positive and negative control, with four 
experimental replicates for each condition. The positive control consisted of Medium 200 phenol 
red free + 100U/ml penicillin-100 µg/ml streptomyocin + 1 ml low serum growth supplement per 
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200 ml phenol red free media. Negative control was the same recipe, but lacked low serum 
growth supplement. Cells were grown for 16 hours before imaging. 
Image Collection  
 Fluorescent images were taken at a magnification of 4x using a Nikon elipse Ti 
microscope. 5 images were randomly taken per well utilizing the automated imaging software 
associated with the microscope, for a total of 120 images. The images were converted to 8 bit, 
mono-image tiffs and exported for further analysis. 
Image Analysis 
 Images were first blinded using a blinding batch file to avoid bias, and then each image 
was subsequently analyzed for areas of excessive overgrowth of cells. These areas impact the 
ability of the software to complete its analysis and were removed from the image pool. Examples 
of images that would be included and excluded can be found below in Figure 3.  
  
Figure 3: HUVEC Tubular Assay Representative Images. (Left) Included in image analysis while (right) removed.  
The remaining images were analyzed for total tubule length using Angiogenesis Analyzer 
plugin for Image J20.  This software quantifies the networks total tubule length through creation 
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of a pixelized version of the network. To create this pixelized network, “three iterations were 
performed with minimum object size set at 50 pixels, minimum branch size at 25 pixels, 
artifactual loop size at 1000 pixels, isolated element threshold at 100 pixels and master segment 
threshold at 30 pixels”, as done by Marquez-Curtis et al.21 An example of a pixelized network 
can be found in Figure 4, below. 
 
Figure 4: Pixelized version of HUVEC Tubular Formation 
The program outputs a variety of data, but the data of interest was total tubular formation 
due to its indication of general angiogenesis. Tubular formation data was then unblinded and 
further analyzed. 
Statistical Analysis 
Statistical Significance was determined using GraphPad Prism version 6 software. Kruskal 
Wallis nonparametric test was used with Dunn’s post-hoc analysis for each experiment. A one-
tailed t-test was utilized to determine significance between the controls with LSGS(Positive) and 
the controls without LSGS(Negative). Significance was established if p < .05. In each case, 
experimental n was between 3 and 4. 
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Protocol Development 
Cited Protocols 
 The dissection component of this protocol is derived from the protocol developed by 
James N. Sleigh et al22 for rapid isolation of mouse dorsal root ganglia. This protocol is mostly 
developed, but aspects of this protocol needed to be re-optimized for this lab and described in a 
higher level of detail. Specifically, the microscopic dissection and removal of DRGs needed 
additional clarity, which will be addressed in this paper. 
 The enzymatic digestion protocol component of this lab is derived from a protocol 
developed by Dr. Popovich’s lab at The Ohio State University, and similarly requires additional 
optimization for its use in our lab.  
Animal Information 
 The mice utilized for the optimization of this protocol were Wild-Type adult males, and 
were grown and cared for in the OSU Laboratory Animal Resources building as training animals. 
All animals were euthanized with CO2 gas, with the secondary form of euthanasia being heart 
puncture. Mice were euthanized immediately prior to dissection to improve the viability of the 
DRGs to be dissected. 
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Gross Dissection and Spinal Column Isolation 
 Following euthanasia, the animal is sprayed with 70% ethanol to reduce contamination 
and reduce hair interfering with the dissection tools (Fig. 5b). An incision through the skin and 
fur should then be made down the center of the dorsal side of the mouse, revealing the 
underlying muscle beneath (Fig. 5c). Following this, an incision is made close to the lower hips 
of the mouse and should be continue up both sides of the spinal column, with the goal of 
separating the spinal column from the rest of the mouse. The connective tissue between the 
viscera and the spinal column should also be severed, with care taken to ensure the DRGs are not 
damaged. Once the incisions have made it up to the neck, the spinal column can be severed at the 
base of the neck and removed from the body of the mouse (Fig. 5d). 
 Once the spinal column is removed, the soft tissue along the sides of the spinal column 
can be removed using small surgical scissors (Fig. 5e). Care should be taken to ensure that the 
spinal column is dorsal side up, to protect the DRGs. The spinous processes can then be revealed 
using a scalpel blade to separate out the soft tissue to make the spinal column cut easier (Fig. 5f). 
At this point, the spinal column can be cut vertically down the center, with care being taken to 
cut directly in the center of the spinous process (Fig. 5g). Deviance to one side or the other can 
result in a loss of yield of DRGs. Once the spinal column is cleaved, the spinal column should be 
placed under a dissecting microscope.  
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a 
Figure 5: Gross Mouse DRG Dissection 
(a) Lay the mouse dorsal side up (b) Spray with 70% ethanol (c) Remove the skin and fur from the area dorsal to 
the spinal column (d) Remove the spinal column from the mouse (e) Remove the excess soft tissue from the sides 
(f) Scrape the tissue off the spinous processes to make the separation easier (g) Cut the spinal column in half 
vertically using a scalpel 
b
 
c
 
d
 
e
 
f
 
g
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Microscopic Dissection and DRG Removal 
 When each half of the spinal column is placed under the dissecting microscope, the spinal 
cord is clearly visible (Fig. 6a). This should be moved to the side using a small pair of forceps to 
reveal the DRGs which are located underneath the spinal cord (Fig. 6b). Each DRG is visible in 
its own socket, and has connections to the spinal cord, and afferents that extend into the socket. 
However, each DRG is covered by a layer of meninges that needs to be removed (Fig. 6c). A 
small pair of scissors should be used to “scoop” out the DRG by severing the afferents that 
extend into the socket, with care taken not to pinch the DRG as that will induce an injured 
phenotype (Fig. 6d).  
 
 
 
 
 
6a 6b 
6c 
6d 
6e 
Figure 6: DRG Microscopic Dissection 
(a) Place one half of the spinal column under the dissection microscope, dorsal side up (b) 
Remove the spinal cord from covering a DRG (c) Remove the meninges (d) Remove the DRG 
from its socket (e) Remove the remaining axons from the DRG 
13 
 
Once the DRG is scooped out, it can be picked up by an axon bundle, and the remaining 
connections can be cut (Fig. 6e). Once the connections are cut, the DRG should be placed in ice 
cold HBSS for the subsequent enzymatic digestion step. 
Enzymatic Digestion 
 Following DRG isolation, the intact DRGs are washed with HBSS to remove blood cells, 
and then enzymatically digested using Dispase(5U/mL) and Collagenase II(200U/mL) for 45 
minutes at 37°C. The cells are then washed again with warm HBSS, and then treated with DNase 
to prevent free DNA from compromised cells that may affect DRG viability. The intact DRGs 
are then triturated vigorously with a pipette for 15 pumps, before the supernatant is removed. 
The supernatant contains the free cells in suspension, and continuing to triturate these results in 
substantial cell death. The remaining cell clumps are then triturated again for another 20 pumps 
to break them up. The resulting suspension and the supernatant are then passed through a 40µm 
cell filter to remove residual debris. The resulting cells are counted utilizing a hemocytometer. 
 
Results 
DMMB Results 
The amount of Chondroitin Sulfate present in the intact and degraded samples of CSA, 
CSB, and CSC was quantified relative to a standard curve from 0 to 250 µg/ml of Chondroitin 
Sulfate-A. The results of this analysis can be found in Figure 7. 
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Figure 7: DMMB Quantification 
 In each group, the intact group at the higher concentration had significantly higher GAG 
concentration than the degraded group. This shows that the degradation protocol was effective, 
and our Chondroitinase- ABC was able to effectively degrade the Chondroitin Sulfate side-
chains. 
Angiogenesis Experiments 
A HUVEC angiogenesis assay was ran for each condition as previously described, and images 
were collected 16 hours after the commencement of the assay. Representative images are displayed below 
in Figure 8.  
  
Figure 8: Representative Tubular Assay Images  
  
CSB 
(a) Positive Control from CSA well plate (b) Negative Control from CSA well plate (c) CSC 
100 µg/ml 
8b
 
8a
 
8c
 
 8a 
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To demonstrate that the tubular formation protocol was working, controls with both 
LSGS (positive control) and without LSGS (negative control) were quantified and analyzed. The 
controls were used to verify that the assay worked for each of the titled groups, as shown below. 
In each condition, the significant difference between the positive control and the negative control 
indicated that the assay was successful. Post assay verification, all data was quantified and 
compared to their respective positive controls, as shown in Figure 9 below.  
 
 
Figure 9: HUVEC Tubular Assay Results 
For the angiogenesis experiments, the only significant difference between any of the 
experimental conditions was between the positive LSGS control and the degraded CSC group at 
a concentration of 100 µg/ml. In addition, there was an increase in total tubule length between 
the positive LSGS control and the degraded groups, but it was not significant. There was also an 
increase in tubule length for the intact condition, but it was also not significant.  
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Protocol Development 
 Following the successful isolation of intact DRGs from a mouse, a live-dead stain was 
performed to determine the relative viability of the isolation procedure. A representative image 
of this is shown below in Figure 10.  
 
Figure 10: Live-Dead for a Whole Intact DRG 
 When the intact DRGs are enzymatically digested, and a cell count of viable DRGs is 
determined utilizing a hemocytometer, the cell count is consistently very low. Figure 12, below, 
is a representative image demonstrating this. 
 
Figure 11: DRG cell count using Hemocytometer 
DRG 
17 
 
Discussion 
Angiogenesis Experiments 
The goal of the angiogenesis experiments in this study were to determine the mechanism 
by which Aggrecan inhibits angiogenesis. Previous literature has shown that intact human 
Aggrecan inhibits cell adhesion and migration in vitro23 and that Aggrecan degrades during IVD 
degeneration24. In addition, a previous study showed that intact and degraded salmon nasal 
cartilage proteoglycan, which is a member of the Aggrecan family, inhibited angiogenesis in 
vitro15.  
In our study, we found no inhibition of angiogenesis for any of our groups. This is not 
surprising, as Aggrecan side chains were utilized for this study rather than whole aggrecan 
protein. Our experiments also did not include the core protein, which is possibly involved in the 
inhibitory process. In addition, the representative side-chains chosen for this study were chosen 
specifically to match those present in human Aggrecan, while those studied by Kobayashi et al 
were based on availability. 
Previous studies have also demonstrated, in some cases, that high concentrations of 
chondroitin sulfates can have pro-angiogenic affects25, due to their ability to mediate growth 
factor-mediated migration and morphogenesis. Our results show that in some cases, even 
degraded chondroitin sulfate can have pro-angiogenic effects. For our high concentration  
Chondroitin Sulfate-C group, a significant increase in tubular formation can be observed in our 
degraded condition. The proposed mechanism for this is that degraded chondroitin-sulfate groups 
contain GAG-peptide fragments, which promote angiogenesis through their supply. Previous 
research has shown that these released fragments can modulate wound healing in a similar 
mechanism26.  
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In addition, the composition of Aggrecan changes as the intervertebral disc ages. 
Chondroitin 6-Sulfate (CSC) goes from relative low concentrations to dominating the 
chondroitin sulfate composition19. This change provides support for the degradation of 
Chondroitin 6-Sulfate playing a significant role in angiogenesis, as the degradation of adult 
Aggrecan and its side-chains is typical of IVD degeneration24. These degraded products, namely 
Chondroitin 6-Sulfate, then produce the angiogenesis that is typical of disease. 
This effect becomes especially interesting when combined with data from Kobayashi et 
al, where they showed that intact salmon Aggrecan inhibits the expression of MMPs, which have 
been shown to actively degrade Aggrecan in vivo27. This means that when Aggrecan becomes 
degraded, it loses its inhibition on MMP expression, and simultaneously some of its degraded 
products promote angiogenesis. In turn, MMPs degrade more Aggrecan, which continues the 
cycle.  
Protocol Development 
 The protocol modified from Sleigh et al, and Dr. Popovich’s lab at OSU, improves upon 
the strengths already present in the procedure, but lack the consistent viability observed in their 
protocols. The modified protocol improves the speed of dissection time, and it reduces the 
complexity and difficulty of the dissection by making the DRGs easier to access and extract. 
Unlike the protocol developed by Sleigh et al, our protocol is achievable with a lower quality of 
surgical tools and has been tested using adult mice. Additionally, the protocol involves steady 
removal of the spinal cord along with the DRGs, which reduces the amount of time that the 
DRGs are exposed to air before being extracted and placed in HBSS.  
 Unfortunately, the protocol developed lacks the consistency of the other protocols 
developed in their ability to consistently yield viable DRGs. Due to time constraints, a protocol 
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able to generate consistent viable DRGs was not able to be developed, and this is of definite 
future interest for this lab.  
Significance and Conclusions 
The results of this study suggest that the side-chain of Aggrecan most prevalent in adult humans 
can promote angiogenesis when degraded. This could have significance in determining the 
mechanism by which angiogenesis, and subsequently, neurogenesis, in the intervertebral disc 
occurs. An understanding of this process could result in more targeted therapeutics that could 
reduce the pathogenesis of pain-related processes.  
Limitations and Future Work 
DRG Cell Viability 
 The described method of DRG isolation improves on the efficiency and simplicity of 
previous methodologies, but lacks the ability to generate consistently viable DRG cells. Future 
work should attempt to manipulate the parameters of the enzymatic digestion protocol, or utilize 
different digestion enzymes and growth media, as seen in other DRG isolation protocols28. 
Angiogenesis Assay 
 While tubular formation assays are a good indicator of angiogenesis, other assays may be 
a better indicator. More functional assays, such as cellular migration, or in vivo matrix assays, 
could provide more insight into the behavior of cells in response to the Chondroitin Sulfate side-
chains.29  
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Future Work 
 Intact Aggrecan has been shown to inhibit neurogenesis and angiogenesis in vitro, and 
degradation of that Aggrecan has been shown to arrest that effect13,15. In this study, we found 
evidence that some degraded chondroitin sulfate chains present on Aggrecan have pro-
angiogenic effects, yet we found no evidence that any of the chains studied have an inhibitory 
effect when left intact. This could be the result of interactions between the side-chains, which 
could be promoting some effect in the local microenvironment only when they are able to 
interact. This experiment would remove those effects, as each side-chain is studied in isolation.  
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